



(43) International Publication Date
31 July 2014 (31.07.2014)

(10) International Publication Number
WO 2014/116070 A1

(51) International Patent Classification:

C07D 401/12 (2006.01) *A61P 35/00* (2006.01)
A61K 31/517 (2006.01)

(21) International Application Number:

PCT/KR2014/000752

(22) International Filing Date:

27 January 2014 (27.01.2014)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

10-2013-0009282 28 January 2013 (28.01.2013) KR

(71) Applicant: HANMI PHARM. CO., LTD. [KR/KR]; 214, Muha-ro, Paltan-myeon, Hwaseong-si, Gyeonggi-do 445-910 (KR).

(72) Inventors: BANG, Keuk Chan; 4304-501, 2, Gwanggyomaeul-ro, Sujji-gu, Yongin-si, Gyeonggi-do 448-130 (KR). JUNG, Jae Hyuk; 302-ho, 65, Guksabong 10-gil, Dongjak-gu, Seoul 156-846 (KR). MOON, Young Ho; 146-1203, 498, Yeongtong-ro, Yeongtong-gu, Suwon-si, Gyeonggi-do 443-740 (KR).

(74) Agent: FIRSTLAW P.C.; 60 Mabang-Ro, Seocho-Ku, Seoul 137-739 (KR).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: METHOD FOR PREPARING 1-(4-(4-(3,4-DICHLORO-2-FLUOROPHENYLAMINO)-7-METHOXYQUINAZOLIN-6-YLOXY)PIPERIDIN-1-YL)PROP-2-EN-1-ONE

(57) Abstract: The present invention relates to a novel method for preparing 1-(4-(4-(3,4-dichloro-2-fluorophenylamino)-7-methoxyquinazolin-6-yloxy)piperidin-1-yl)prop-2-en-1-one in a simpler process as compared with conventional methods by allowing 4-(3,4-dichloro-2-fluorophenylamino)-7-methoxyquinazolin-6-ol to react with an N-acyl piperidine derivative in an inert polar protic solvent in the presence of a base.



WO 2014/116070 A1

DESCRIPTION


METHOD FOR PREPARING 1-(4-(4-(3,4-DICHLORO-2-FLUOROPHENYLAMINO)-7-METHOXYQUINAZOLIN-6-YLOXY)PIPERIDIN-1-YL)PROP-2-EN-1-ONE


FIELD OF THE INVENTION

The present invention relates to a novel method for preparing 1-(4-(4-(3,4-dichloro-2-fluorophenylamino)-7-methoxyquinazolin-6-yloxy)piperidin-1-yl)prop-2-en-1-one, a free base form of a specific drug (hydrochloride form) which can selectively and effectively inhibit drug resistance induced by the growth of cancer cells and tyrosine kinase mutations. By the inventive method the target compound can be prepared in a much simpler process as compared with conventional methods.

BACKGROUND OF THE INVENTION


1-(4-(4-(3,4-dichloro-2-fluorophenylamino)-7-methoxyquinazolin-6-yloxy)piperidin-1-yl)prop-2-en-1-one hydrochloride, as represented by formula (IV) below, is known to have anti-proliferative activities such as anti-cancer activities, and it is considered as an important drug that can selectively and effectively inhibit drug resistance which is induced by cancer cell growth and tyrosine kinase mutations. The free base form of the compound of formula (IV), *i.e.*, 1-(4-(4-(3,4-dichloro-2-fluorophenylamino)-7-methoxyquinazolin-6-yloxy)piperidin-1-yl)prop-2-en-1-one, as represented by formula (I) below, is also known as CAS Registry No. 1092364-38-9.





The compound of formula (I) above may be prepared by the method disclosed in KR Patent No. 1013319, and the detailed reaction process is described in Reaction Scheme 1 below. The compound of formula (I) prepared by Reaction Scheme (I) below may be reacted with hydrochloric acid to yield a hydrochloride salt thereof, *i.e.*, the compound of formula (IV):

Reaction Scheme 1



wherein R is halogen.

According to the preparation method as described in Reaction Scheme 1 above, compound **10** is subjected to a condensation reaction with formamidine

hydrochloride at a high temperature, *e.g.*, 210°C, to yield compound **9**, which is then allowed to react with L-methionine in an organic acid such as methylsulfonic acid, whereby the methyl group at the C-6 position of compound **9** is removed to obtain compound **8**.

5 Subsequently, compound **8** is subjected to a protection reaction in anhydrous acetic acid and a base such as pyridine to produce compound **7**, which is then subjected to a reaction with inorganic acids such as thionyl chloride, phosphorus oxychloride and the like in the presence of a catalytic amount of *N,N*-dimethylformamide under a reflux condition to obtain compound **6** in a
10 hydrochloride form.

Compound **6** thus obtained is subjected to a deprotection reaction by stirring in an alcohol solution containing ammonia (*e.g.*, 7N ammonia methanol solution) to produce compound **5**. Compound **5** is subjected to a Mitsunobu reaction with *tert*-butyl 4-hydroxypiperidine-1-carboxylate compound to yield compound **4**, which is
15 then subjected to a substitution reaction with aniline in an organic solvent such as 2-propanol or acetonitrile to obtain compound **3**. Compound **3** is subjected to a reaction with an organic acid such as trifluoroacetic acid or an inorganic acid such as strong hydrochloric acid in an organic solvent such as dichloromethane, whereby the *t*-butoxycarbonyl group is deprotected to obtain compound **2**. In the
20 Mitsunobu reaction above, diisopropyl azodicarboxylate, diethyl azodicarboxylate or di-*t*-butyl azodicarboxylate, and triphenylphosphine may be used.

Compound **1**, *i.e.*, the compound of formula (I) of the present invention, is prepared by subjecting compound **2** thus obtained to an acylation reaction with acryloyl chloride in a mixture of water and an organic solvent such as
25 tetrahydrofuran and the like, or in dichloromethane in the presence of an inorganic base such as sodium bicarbonate or an organic base such as pyridine or triethylamine. Alternatively, compound **2** is subjected to a condensation reaction with acrylic acid by using a coupling agent, *e.g.*, 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide (EDC) or 2-(1H-7-azabenzotriazol-1-yl)-
30 1,1,3,3-tetramethyluronium hexafluorophosphate methanaminium (HATU).

In accordance with the above-described method, however, the step for preparing compound **9** may be hazardous because this step is conducted at a high temperature without a solvent, and the reaction may not proceed uniformly. Also, an excessive amount of thionyl chloride is used in the step for preparing compound

5, rendering the subsequent steps difficult. Therefore, this method is not suitable for commercialization.



The most notable drawback to this method for preparing compound 1 is that the yield of the acrylization reaction is very low, *e.g.*, 13%, and also the reaction is accompanied by a number of side reactions, and thus, it requires a purification process by using column chromatography. Also, in the case where compound 3 is prepared by the Mitsunobu reaction, various by-products may be formed, which necessitate a purification step by using column chromatography that requires expensive silica gel and an excessive amount of mobile phase solvents. Therefore, this method is not feasible for commercialization.


Accordingly, the present inventors have endeavored to develop a novel method for preparing the compound of formula (I) in high purity and high yield, which is economical and feasible for commercialization as well.

SUMMARY OF THE INVENTION

Therefore, it is an object of the present invention to provide a novel and simple method for preparing 1-(4-(4-(3,4-dichloro-2-fluorophenylamino)-7-methoxyquinazolin-6-yloxy)piperidin-1-yl)prop-2-en-1-one.

In accordance with one aspect of the present invention, there is provided a method for preparing the compound of formula (I), which comprises the step of allowing the compound of formula (II) to react with the compound of formula (III) in an inert polar protic solvent in the presence of a base:






wherein X is tosyloxy (OTs), mesyloxy (OMs), trifluoromethane sulfonate, fluorosulfonate or halogen; and Y is ethenyl or halogenoethyl.

5 DETAILED DESCRIPTION OF THE INVENTION

According to the method of the present invention, the compound of formula (I), *i.e.*, 1-(4-(4-(3,4-dichloro-2-fluorophenylamino)-7-methoxyquinazolin-6-yloxy)piperidin-1-yl)prop-2-en-1-one, can be prepared by allowing the compound of formula (II), *i.e.*, 4-(3,4-dichloro-2-fluorophenylamino)-7-methoxyquinazolin-6-ol, to react with the compound of formula (III) in an inert polar protic solvent in the presence of a base. This mechanism is described in Reaction Scheme 2 below:

Reaction Scheme 2



wherein X and Y are the same as defined above.

Particular examples of the inert polar protic solvent used in the above reaction include *N,N*-dimethylformamide, *N,N*-dimethylacetamide, *N*-methylpyrrolidin-2-one, dimethyl sulfoxide and a mixture thereof.

Particular examples of the base used in the above reaction is alkali metal carbonates such as sodium bicarbonate, potassium carbonate, cesium carbonate and a mixture thereof. Preferably, the base is used in an amount of 1 to 5 mole equivalents based on 1 mole equivalent of the compound of formula (II).


The above reaction may be conducted at a temperature of 60°C to 100°C, preferably 70°C to 90°C, more preferably 70°C to 80°C.

The compound of formula (II), which is used as a starting material in the present invention, can be prepared by the following steps (*see* Reaction Scheme 3 below):

(i) subjecting a compound of formula (VII) to a reaction with a halogenating agent in the presence of an organic base to produce the compound of formula (VI), which is then subjected to a reaction with a compound of formula (VIII) to obtain the compound of formula (V), *i.e.*, 4-(3,4-dichloro-2-fluorophenylamino)-7-methoxyquinazolin-6-yl acetate; and

(ii) subjecting the compound of formula (V) to a reaction with an ammonia solution in a polar protic solvent.

Reaction Scheme 3



Particular examples of the organic base used in Step (i) above include diisopropylamine, triethylamine, diisopropylethylamine, diethylamine, pyridine, 4-dimethylpyridine, morpholine and a mixture thereof. Particular examples of the halogenating agent include thionyl chloride, phosphorus oxychloride and a mixture thereof. The above reaction may be conducted at 50°C to 150°C, preferably 60°C to 90°C, more preferably at about 75°C. In this step, the compound of formula (VI) is prepared in the form of a solution containing it in an organic solvent, rather than an isolated form. Subsequently, the compound of formula (VI) contained in the organic solvent is allowed to react with the compound of formula (VIII) to obtain the compound of formula (V), *i.e.*, 4-(3,4-dichloro-2-fluorophenylamino)-7-methoxyquinazolin-6-yl acetate.


The compound of formula (VII), which is used as a starting material of the above reaction, can be prepared by the method disclosed in Korean Patent No. 1013319.

In the subsequent step (ii), the compound of formula (V) prepared in the previous step (i) is allowed to react with an ammonia solution or ammonia gas in a

polar protic solvent (*e.g.*, methanol, ethanol, propanol and a mixture thereof) at a temperature of 0°C to 40°C, preferably 10°C to 30°C, more preferably at about 25°C, to obtain 4-(3,4-dichloro-2-fluorophenylamino)-7-methoxyquinazolin-6-ol of formula (II).

Also, the compound of formula (III), which is used as a starting material of the present invention, can be prepared by allowing the compound of formula (IX) or its salt to react with the compound of formula (X) in the presence of a base or an amide coupling agent (*see* Reaction Scheme 4 below):

Reaction Scheme 4



wherein X and Y are the same as defined above; and Z is halogen or hydroxyl.

The above reaction can be conducted in an organic solvent such as tetrahydrofuran, ethyl acetate, acetone, 1,4-dioxane, acetonitrile, dichloromethane, carbon tetrachloride, chloroform, *N,N*-dimethyl formamide or dimethylsulfoxide, or in a mixture of an organic solvent and water.

Particular examples of the base include an inorganic base such as sodium carbonate, sodium bicarbonate, calcium carbonate, potassium carbonate, sodium hydroxide, potassium hydroxide and cesium carbonate, an organic base such as diisopropylamine, triethylamine, diisopropylethylamine and diethylamine, and a mixture thereof. Particular examples of the amide coupling agent include 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide, hydroxybenzotriazole, *O*-(7-azabenzotriazol-1-yl)-*N,N,N',N'*-tetramethyluronium hexafluorophosphate, *N,N'*-dicyclohexylcarboimide, 1-hydroxy-7-azabenzotriazole, *N,N'*-diisopropylcarboimide, (benzotriazol-1-yloxy)tris(dimethylamino)phosphonium hexafluorophosphate and a mixture thereof. The base or amide coupling agent may be used in an amount of 3 to 5 mole equivalents based on 1 mole equivalent of the compound of formula (IX) or a salt thereof.

The salt of the compound of formula (IX) above is preferably a hydrochloride salt (2HCl salt) or a hydrobromide salt (2HBr salt). The above reaction may be conducted at a temperature of -30°C to 30°C, preferably about 0°C to room temperature, by stirring for a suitable period of time.


In accordance with the method of the present invention, the target compound of formula (I), 1-(4-(4-(3,4-dichloro-2-fluorophenylamino)-7-methoxyquinazolin-6-yloxy)piperidin-1-yl)prop-2-en-1-one, can be prepared in high purity and high yield by a simple method.

Moreover, 1-(4-(4-(3,4-dichloro-2-fluorophenylamino)-7-methoxyquinazolin-6-yloxy)piperidin-1-yl)prop-2-en-1-one hydrochloride, which can selectively and effectively inhibit drug resistance induced by the growth of cancer cells and tyrosine kinase mutations, can be prepared by allowing the compound of formula (I) to react with hydrochloric acid in an organic solvent (*e.g.*, methanol, ethanol, propanol, isopropanol, butanol, ethyl acetate, acetone, tetrahydrofuran, acetonitrile, 1,4-dioxane and a mixture thereof) at a temperature of 0°C to 60°C, preferably 10°C to 40°C, more preferably at about 25°C.

Hereinafter, the present invention is described more specifically by the following Examples, but these are provided only for illustration purposes, and the present invention is not limited thereto.

Preparation Example 1: Preparation of 4-(3,4-dichloro-2-fluorophenylamino)-7-methoxyquinazolin-6-ol, the compound of formula (II)

Step (i): Preparation of 4-(3,4-dichloro-2-fluorophenylamino)-7-methoxyquinazolin-6-yl acetate, the compound of formula (V)




7-methoxy-4-oxo-3,4-dihydroquinazolin-6-yl acetate (100 g) was added to toluene (850 mL) and *N,N*-diisopropylethylamine (82.5 mL). Phosphorus

oxychloride (100 mL) was added thereto over 20 minutes at 75°C, followed by stirring for 3 hours. Toluene (450 mL) and 3,4-dichloro-2-fluoroaniline (84.6 g) were added to the resulting mixture, followed by stirring for 2 hours. Upon completion of the reaction, the resulting mixture was cooled to 25°C, and the solid thus obtained was filtered under a reduced pressure and washed with toluene (400 mL). Isopropanol (1,000 mL) was added to the solid, and the resulting mixture was stirred for 2 hours. The solid thus obtained was filtered and washed with isopropanol (400 mL), and then was dried at 40°C in an oven to obtain the target compound (143 g, yield: 83%).

¹H-NMR (DMSO-d₆, 300 MHz, ppm) δ 8.92 (s, 1H), 8.76 (s, 1H), 7.69-7.57 (m, 3H), 4.01 (s, 3H), 2.38 (s, 3H).

Step (ii): Preparation of 4-(3,4-dichloro-2-fluorophenylamino)-7-methoxyquinazolin-6-ol, the compound of formula (II)




4-(3,4-dichloro-2-fluorophenylamino)-7-methoxyquinazolin-6-yl acetate (100 g) prepared in step (i) was admixed with methanol (1,000 mL). The mixture was cooled to 10 to 15°C, added with an ammonia solution (460 g), and stirred for 3 hours at 25°C. The solid thus obtained was filtered and washed with a mixed solvent of methanol (200 mL) and water (200 mL). The resulting solid was dried at 40°C in an oven to obtain the target compound (74 g, yield: 83%).

¹H-NMR (DMSO-d₆, 300 MHz, ppm) δ 9.57 (br, 2H), 8.35 (s, 1H), 7.68 (s, 1H), 7.61-7.52 (m, 2H), 7.21 (s, 1H), 3.97 (s, 3H).

Example 1: Preparation of 1-(4-(4-(3,4-dichloro-2-fluorophenylamino)-7-methoxyquinazolin-6-yloxy)piperidin-1-yl)prop-2-en-1-one, the compound of formula (I)


Step (1-1): Preparation of 1-acryloylpiperidin-4-yl 4-methylbenzenesulfonate, the compound of formula (III)



Piperidin-4-yl 4-methylbenzenesulfonate hydrochloride (200 g, 685 mmol), tetrahydrofuran (THF, 1.6 L) and NaHCO_3 (172 g, 2047 mmol) were added to water (2 L), and the mixture was cooled to 0°C . A solution prepared by adding acryloyl chloride (56 mL, 519 mmol) to THF (0.4 L) was added thereto over 30 minutes, followed by stirring for 1 hour. Upon completion of the reaction, MeOH (0.4 L) was added thereto for quenching. The solution was extracted with ethyl ester (2 L), and washed with water (2 L). The organic layer was separated, distilled under a reduced pressure, and the residue thus obtained was recrystallized from dichloromethane-hexane to obtain the target compound (174 g, yield: 82%).

$^1\text{H-NMR}$ (300 MHz, DMSO-d_6) δ 7.82 (d, 2H), 7.48 (d, 2H), 6.80-6.71 (m, 1H), 6.10-6.03 (m, 1H), 5.67-5.62 (m, 1H), 4.76-4.71 (m, 1H), 3.70-3.68 (m, 2H), 3.43-3.31 (m, 2H), 2.42 (s, 3H), 1.73 (m, 2H), 1.52 (m, 2H).

Step (1-2): Preparation of 1-(4-(4-(3,4-dichloro-2-fluorophenylamino)-7-methoxyquinazolin-6-yloxy)piperidin-1-yl)prop-2-en-1-one, the compound of formula (I)




4-(3,4-dichloro-2-fluorophenylamino)-7-methoxyquinazolin-6-ol (12 g, 34 mmol) prepared in Preparation Example 1, 1-acryloylpiperidin-4-yl 4-methylbenzenesulfonate (16 g, 51 mmol) prepared in step (1-1), K_2CO_3 (9.4 g, 68 mmol) and dimethylacetamide (DMAc, 300 mL) were admixed. The reaction temperature was raised to 70°C , and the mixture was stirred for 24 hours. Upon completion of the reaction, the mixture was cooled down to room temperature, extracted with ethyl ester (300 mL), and then washed with water (300 mL). The

organic layer was separated, and distilled under a reduced pressure. The residue thus obtained was solidified by adding ethyl ester, filtered, and dried to obtain the target compound (12.8 g, yield: 77%).

¹H-NMR (300 MHz, DMSO-d₆) δ 9.65 (bs, 1H), 8.40 (s, 1H), 7.88 (s, 1H), 7.64-7.56 (m, 2H), 7.24 (s, 1H), 6.89-6.80 (m, 1H), 6.15-6.08 (m, 1H), 5.70-5.66 (m, 1H), 4.78 (m, 1H), 3.94 (s, 3H), 3.87 (m, 2H), 3.48 (m, 2H), 2.03 (m, 2H), 1.70 (m, 1H).

Example 2: Preparation of 1-(4-(4-(3,4-dichloro-2-fluorophenylamino)-7-methoxyquinazolin-6-yloxy)piperidin-1-yl)prop-2-en-1-one, the compound of formula (I)


Step (2-1): Preparation of 1-(3-chloropropanoyl)piperidin-4-yl 4-methylbenzenesulfonate, the compound of formula (III)



Piperidin-4-yl 4-methylbenzenesulfonate hydrochloride (20 g, 68 mmol) and dichloromethane (200 mL) were admixed and the mixture was cooled down to 0°C. Triethylamine (29 mL, 205 mmol) and 3-chloropropionyl chloride (7.9 mL, 82 mmol) were added thereto, followed by stirring for 16 hours at room temperature. Upon completion of the reaction, the reaction mixture was extracted with ethyl ester (200 mL), and washed with water (200 mL). The organic layer was separated, distilled under a reduced pressure, and the residue thus obtained was purified to obtain the target compound (18 g, yield: 76%).

¹H-NMR (300 MHz, CDCl₃) δ 7.80 (d, 2H), 4.76-4.72 (m, 1H), 3.80 (t, 2H), 3.64-3.57 (m, 3H), 3.40 (m, 1H), 2.77 (t, 2H), 2.46 (s, 3H), 1.85-1.70 (m, 4H).

Step (2-2): Preparation of 1-(4-(4-(3,4-dichloro-2-fluorophenylamino)-7-methoxyquinazolin-6-yloxy)piperidin-1-yl)prop-2-en-1-one, the compound of formula (I)






5 The procedure of Step (1-2) of Example 1 was repeated, except 1-(3-chloropropanoyl)piperidin-4-yl 4-methylbenzenesulfonate (13 g, 35 mmol) prepared in step (2-1) above was used instead of 1-acryloylpiperidin-4-yl 4-methylbenzenesulfonate (16 g, 51 mmol) prepared in step (1-1), to obtain the target compound (7.4 g, yield: 58%).

10

¹H-NMR (300 MHz, DMSO-d₆) δ 9.65 (bs, 1H), 8.40 (s, 1H), 7.88 (s, 1H), 7.64-7.56 (m, 2H), 7.24 (s, 1H), 6.89-6.80 (m, 1H), 6.15-6.08 (m, 1H), 5.70-5.66 (m, 1H), 4.78 (m, 1H), 3.94 (s, 3H), 3.87 (m, 2H), 3.48 (m, 2H), 2.03 (m, 2H), 1.70 (m, 1H).

WHAT IS CLAIMED IS:





1. A method for preparing the compound of formula (I), which comprises the step of allowing the compound of formula (II) to react with the compound of formula (III) in an inert polar protic solvent in the presence of a base:





wherein X is tosyloxy (OTs), mesyloxy (OMs), trifluoromethane sulfonate, fluorosulfonate or halogen; and Y is ethenyl or halogenoethyl.

2. The method of claim 1, wherein the inert polar protic solvent is selected from the group consisting of *N,N*-dimethylformamide, *N,N*-dimethylacetamide, *N*-methylpyrrolidin-2-one, dimethyl sulfoxide and a mixture thereof.
3. The method of claim 1, wherein the base is an alkali metal carbonate selected from the group consisting of sodium bicarbonate, potassium carbonate, cesium carbonate and a mixture thereof.
4. The method of claim 1, wherein the base is used in an amount of 1 to 5 mole equivalents based on 1 mole equivalent of the compound of formula (II).
5. The method of claim 1, wherein the compound of formula (II) is prepared by (i) subjecting a compound of formula (VII) to a reaction with a halogenating agent in the presence of an organic base to produce the compound of formula (VI), which

is then subjected to a reaction with a compound of formula (VIII) to obtain the compound of formula (V); and (ii) subjecting the compound of formula (V) to a reaction with an ammonia solution in a polar protic solvent:



6. The method of claim 5, wherein the organic base is selected from the group consisting of diisopropylamine, triethylamine, diisopropylethylamine, diethylamine, pyridine, 4-dimethylpyridine, morpholine and a mixture thereof.
7. The method of claim 5, wherein the halogenating agent is selected from the group consisting of thionyl chloride, phosphorus oxychloride and a mixture thereof.
8. The method of claim 5, wherein the polar protic solvent is selected from the group consisting of methanol, ethanol, propanol and a mixture thereof.
9. The method of claim 1, wherein the compound of formula (III) is prepared by allowing the compound of formula (IX) or its salt to react with the compound of formula (X) in the presence of a base or an amide coupling agent:



wherein X and Y are the same as defined in claim 1; and Z is halogen or hydroxyl.

10. The method of claim 9, wherein the reaction between the compound of formula (IX) or its salt and the compound of formula (X) is conducted in an organic solvent or a mixture of an organic solvent and water; and the organic solvent is tetrahydrofuran, ethyl acetate, acetone, 1,4-dioxane, acetonitrile, dichloromethane, carbon tetrachloride, chloroform, *N,N*-dimethyl formamide or dimethylsulfoxide.
11. The method of claim 9, wherein the base used in the reaction between the compound of formula (IX) or its salt and the compound of formula (X) is selected from the group consisting of sodium carbonate, sodium bicarbonate, calcium carbonate, potassium carbonate, sodium hydroxide, potassium hydroxide, cesium carbonate, diisopropylamine, triethylamine, diisopropylethylamine, diethylamine, and a mixture thereof
12. The method of claim 9, wherein the amide coupling agent is selected from the group 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide, hydroxybenzotriazole, *O*-(7-azabenzotriazol-1-yl)-*N,N,N',N'*-tetramethyluronium hexafluorophosphate, *N,N'*-dicyclohexylcarboimide, 1-hydroxy-7-azabenzotriazole, *N,N'*-diisopropylcarboimide, (benzotriazol-1-yloxy)tris(dimethylamino)phosphonium hexafluorophosphate and a mixture thereof.
13. The method of claim 9, wherein the salt of the compound of formula (IX) is a hydrochloride or hydrobromide salt.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/KR2014/000752**A. CLASSIFICATION OF SUBJECT MATTER****C07D 401/12(2006.01)i, A61K 31/517(2006.01)i, A61P 35/00(2006.01)i**

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

C07D 401/12; C07C 69/604; C07D 403/12; C07D 401/14; A61K 31/517; A61P 35/00

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Korean utility models and applications for utility models

Japanese utility models and applications for utility models

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

eKOMPASS(KIPO internal) & Keywords: 1-(4-(4-(3,4-dichloro-2-fluorophenylamino)-7-methoxyquinazolin-6-yloxy)piperidin-1-yl)prop-2-en-1-one

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 2012-169733 A1 (HANMI PHARM. CO., LTD. et al.) 13 December 2012. See abstract, claims 14-16, and the entire document	1-13
A	WO 2011-155793 A2 (HANMI HOLDINGS CO., LTD. et al.) 15 December 2011. See abstract, claims 1-16, and the entire document	1-13
A	WO 2008-150118 A2 (HANMI PHARM. CO., LTD. et al.) 11 December 2008. See abstract, claims 1-6, and the entire document	1-13
A	CHA M. Y. et al., `Antitumor activity of HM781-36B, a highly effective pan-H ER inhibitor in erlotinib-resistant NSCLC and other EGFR-dependent cancer models`, International Journal of Cancer, 2012, 130(10), 2445-2454. See abstract, page 2447 (Table 1)	1-13



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

08 May 2014 (08.05.2014)

Date of mailing of the international search report

09 May 2014 (09.05.2014)

Name and mailing address of the ISA/KR


International Application Division
Korean Intellectual Property Office
189 Cheongsu-ro, Seo-gu, Daejeon Metropolitan City, 302-701,
Republic of Korea

Facsimile No. +82-42-472-7140

Authorized officer

LEE, Jae Jeong

Telephone No. +82-42-481-3488



INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No.

PCT/KR2014/000752

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 2012-169733 A1	13/12/2012	AR 086851 A1	29/01/2014
		AU 2012-267642 A1	30/01/2014
		CA 2837703 A1	13/12/2012
		CN 103596940 A	19/02/2014
		CO 6852070 A2	30/01/2014
		KR 10-1317809 B1	16/10/2013
		KR 20120135777 A	17/12/2012
		TW 201302201 A	16/01/2013
WO 2011-155793 A2	15/12/2011	AR 081870 A1	24/10/2012
		AU 2011-262662 A1	31/01/2013
		CA 2801631 A1	15/12/2011
		CN 102933573 A	13/02/2013
		CO 6620015 A2	15/02/2013
		EP 2580206 A2	17/04/2013
		EP 2580206 A4	22/01/2014
		JP 2013-531648 A	08/08/2013
		KR 10-1217526 B1	02/01/2013
		KR 20110135685 A	19/12/2011
		MA 34368 B1	03/07/2013
		MX 2012014440 A	26/02/2013
		PE 02362013 A1	18/03/2013
		SG 185661 A1	28/12/2012
		TW 201204711 A	01/02/2012
		US 2013-0071452 A1	21/03/2013
		WO 2011-155793 A3	26/04/2012
WO 2008-150118 A2	11/12/2008	AR 066876 A1	16/09/2009
		AU 2008-260772 A1	11/12/2008
		AU 2008-260772 B2	02/06/2011
		CA 2687180 A1	11/12/2008
		CA 2687180 C	24/07/2012
		CN 101679384 A	24/03/2010
		CN 101679384 B	16/10/2013
		EP 2167492 A2	31/03/2010
		EP 2167492 A4	15/12/2010
		IL 202154 D0	16/06/2010
		JP 05-155391B2	06/03/2013
		JP 2010-529115 A	26/08/2010
		JP 2010-529115 T	26/08/2010
		KR 10-1013319 B1	09/02/2011
		KR 20080107294 A	10/12/2008
		MX 2009012772 A	15/12/2009
		MY 144972 A	30/11/2011
		NZ 582412 A	22/12/2011
		RU 2009149307 A	20/07/2011
		RU 2434010 C2	20/11/2011
		TW 200906414 A	16/02/2009
		TW I377944 B	01/12/2012

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No.

PCT/KR2014/000752Patent document
cited in search reportPublication
datePatent family
member(s)Publication
date

US 2010-0179120 A1

15/07/2010

US 8188102 B2

29/05/2012

WO 2008-150118 A3

29/01/2009